For the full cohort as well as the subgroup of patients with low‐ to intermediate‐grade PC, ZNF660 improved Harrell's C‐index when combined with clinicopathological parameters, although it was only borderline significant or nonsignificant in multivariate Cox regression analyses (Tables 2 and 3). Here, ZNF660 is linked to pachyonychia congenita.